# OnCo record tapur (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/tapur/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "tapur", "NCT02693535" ;
  schema:name "TAPUR (Targeted Agent and Profiling Utilization Registry)"@en ;
  schema:alternateName "TAPUR Study"@en, "ASCO TAPUR"@en ;
  schema:description "TAPUR is the American oncology society's own trial: when a genomic test finds a change that an already approved drug targets in a different cancer, the drug's maker supplies it free and the outcome is recorded. It turns off-label guesses into organised evidence, and has told the field which matches work and which do not."@en ;
  schema:url <https://onco.cc/trials/tapur/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02693535>, <https://www.tapur.org>, <https://doi.org/10.1200/PO.22.00306>, <https://doi.org/10.1200/PO.20.00037>, <https://doi.org/10.1200/PO.23.00615> ;
  onco:status "recruiting" ;
  onco:phase "2" ;
  schema:startDate "2016-03-14" ;
  onco:cancers <https://onco.cc/terms/rare-cancers/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/variant-knowledgebases/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/erlotinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/boehringer-ingelheim/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/taiho/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/real-world-evidence/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ahn-jco-precis-oncol/>, <https://onco.cc/key-papers/paper-gupta-jco-precis-oncol/>, <https://onco.cc/key-papers/paper-perez-jco-precis-oncol/> .